German-based Evotec and Austria-based Apeiron Biologics have signed a research partnership focused on cancer immunotherapy.

The research collaboration will focus on developing immunomodulatory lead compounds for cancer treatment.

Evotec chief operating officer Dr Mario Polywka said; "We look forward to continue working with Apeiron on this important project. The collaboration highlights the strength of Evotec’s phenotypic screening capabilities to identify novel mechanisms and hits in important therapeutic areas."

"The research collaboration will focus on developing immunomodulatory lead compounds for cancer treatment."

Apeiron Biologics will contribute its in-vitro and in-vivo pharmacology knowledge to the research, while Evotec will provide medicinal chemistry as well as chemical proteomics.

The collaboration occured following the successful outcome of a phenotypic high throughput screen, which Apeiron Biologics previously commissioned to Evotec.

Apeiron Biologics chief executive officer Dr Hans Loibner said the company is looking forward to refining the target compounds in the collaboration using its own immunological expertise.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"There is no doubt that immunomodulatory compounds like these carry huge therapeutic and commercial potential," Loibner said.

Financial details of the transaction were not disclosed.